AstraZeneca: FDA approves Lumoxiti for rare blood cancer
(CercleFinance.com) - The US Food and Drug Administration said that it has approved AstraZeneca's Lumoxiti injection for intravenous use, which the health regulator defines as a new kind of treatment for hairy cell leukemia.
The FDA has approved Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, it said, including treatment with a purine nucleoside analog.
HCL is a rare, slow-growing blood cancer, in which the bone marrow makes too many lymphocytes, a type of white blood cell that fights infection.
The FDA had previously granted Lumoxiti fast track and priority review designations, with the medicine also receiving orphan drug designation.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The FDA has approved Lumoxiti for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, it said, including treatment with a purine nucleoside analog.
HCL is a rare, slow-growing blood cancer, in which the bone marrow makes too many lymphocytes, a type of white blood cell that fights infection.
The FDA had previously granted Lumoxiti fast track and priority review designations, with the medicine also receiving orphan drug designation.
Copyright (c) 2018 CercleFinance.com. All rights reserved.